Current Status
Not Enrolled
Price
Free
Get Started

Program Director

Khalid Al Rasadi, MD

Program Director

Raul D Santos, MD, MSc, PhD

2020 Middle East Summit on Residual Cardiovascular Risk

Cardiovascular diseases remain the #1 cause of death and disability globally and are on the rise in developing regions of the world. Despite advances in the control of the classic risk factors like lowering LDL-Cholesterol and efforts to manage contributing disease factors such as diabetes, obesity and hypertension, patient risk for developing ASCVD can still remain high. This course was designed to educate on the complete examination and clinical approaches to the treatment of residual risk (RR) factors that may persist and ultimately continue to drive the patient’s potential for cardiovascular events.

The IAS is pleased to present thirteen (13) recordings from the live accredited sessions presented at the 2020 Middle East Residual Risk Cardiovascular Summit held in Dubai on February 21-22, 2020. This comprehensive educational event was designed for medical professionals in the clinical setting.

The IAS is very grateful to Biologix FzCo for supporting the 2020 Middle East Residual Risk Cardiovascular Summit through an unrestricted educational grant. We also thank all the speakers and participants for sharing their experience and for helping IAS to develop this global faculty of experts featured in the presentations.

Pre-activity information

Not available

Video 2- Combating Atherosclerosis: Assessing CV Patient Risk for the T2DM Patient

Not available

Video 1 – The History in the Battle of Insulin and Glucagon

Not available

Futuras terapias para o tratamento da dislipidemia (Video 9 – Future Therapies for Dyslipidemia Treatment)

Not available

Uso de inibidores de PCSK9 em pacientes com hipercolesterolemia familiar (Video 8 – Use of PCSK9 Inhibitors in Familial Hypercholesterolemia Patients)

Not available

Video 5 – Impact of Blocking Circulating PCSK9 with Monoclonal Antibodies on Atherogenic Lipoproteins

Not available

影片9 – 血脂异常的未来疗法

Not available

影片8 – 在家族性高胆固醇血症患者中使用PCSK9抑制剂

Not available

影片7 – 急性冠状动脉综合症后,单克隆PCSK9抑制剂早期使用的疗效,可行性和安全性

Not available

影片6 – PCSK9抑制在非常高危患者中的影响以及如何提高成本效益

Not available

影片5 – 利用单克隆抗体阻断PCSK9循环对动脉粥样化脂蛋白的影响

Not available

影片4 – 密集地降低LDL胆固醇的安全性

Not available

影片3 – 预防ASCVD越低的LDL胆固醇越好

Not available

影片2 – 全世界胆固醇控制悲伤和不足的事实

Not available

影片1 – LDL胆固醇作为ASCVD病因的证据

Not available

Futuras terapias para el tratamiento de la dislipidemia (Video 9 – Future Therapies for Dyslipidemia Treatment)

Not available

Uso de inhibidores de PCSK9 en pacientes con hipercolesterolemia familiar (Video 8 – Use of PCSK9 Inhibitors in Familial Hypercholesterolemia Patients)

Not available

Eficacia, viabilidad y seguridad del uso temprano de inhibidores monoclonales de PCSK9 después de un síndrome coronario agudo (Video 7 – Efficacy, Feasibility and Safety of Early Use of Monoclonal PCSK9 Inhibitors After an Acute Coronary Syndrome)

Not available

Impacto de la inhibición de PCSK9 en pacientes de muy alto riesgo y cómo aumentar la rentabilidad (Video 6 – Impact of PCSK9 Inhibition in Very High-Risk Patients and How to Increase Cost Effectiveness)

Not available

Impacto del bloqueo de la PCSK9 circulante con anticuerpos monoclonales sobre las lipoproteínas aterogénicas (Video 5 – Impact of Blocking Circulating PCSK9 with Monoclonal Antibodies on Atherogenic Lipoproteins)

Not available

Seguridad de la reducción intensiva de LDL-C (Video 4 – Safety of Intensive LDL-C Reduction)

« » page 1 / 9